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Background
Methylthioadenosine (MTA) has anti-oxidant and anti-
proliferative properties and was shown to induce cell
protection in hepatic cells. We previously demonstrated
that exert immunomodulatory and neuroprotective
effects in the animal model of Multiple Sclerosis (MS)
and other neurological diseases like Parkinson disease,
stroke and Epilepsy.
Objective
To study the mechanisms of action and different path-
ways implicated in the neuroprotective effect of MTA in
neurological diseases.
Methods
RN22 (Schwnoma cell line) and PC12 (Pheochromocy-
toma cell line) were used to test the neuroprotective
activity of MTA against stress in RN22 and to differenti-
ate neurites in PC12. BV2 cells were used to test the
effect of MTA in microglia. Organotypic cerebellum cul-
tures were used to determine MTA effect in demyelina-
tion/remyelination. Luminex technology, western blot
and ELISA were used in order to study the phosphory-
lated state of different pathways (AkT/PKB, ERK/MAPK,
P38/SAPK or STAT3) and to determine the amount of
different cytokines (IL-1b and TNF-a). Ros determina-
tion was also done by fluorescence determination.
Results
In vitro studies revealed that MTA protection against dif-
ferent stresses and its capacity to differentiate neurites
implies pathways like ERK/MAPK, P38/SAPK or STAT3.
MTA neuroprotective capacity is also related with its abil-
ity to reduce ROS production and oxidative stress. MTA
was shown to protect against demyelination in cerebellum
organotypic cultures treated with LPS or Lysolecithin.
Conclusions
MTA is neuroprotective in models of MS, Parkinson dis-
ease, stroke or Epilepsy. This neuroprotective effect
depends on its capacity to protect against demyelination,
its anti-oxidant effect and the activation of pathways
related with protection against stress and production of
neurite differentiation.
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